# REVIVE: Replens Versus Intra-Vaginal Estrogen for the Treatment of Vaginal Dryness on Aromatase Inhibitor Therapy

> **NCT01984138** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Polly A. Niravath, MD** · enrollment: 33 (actual)

## Conditions studied

- Estrogen Receptor Positive Breast Cancer
- Breast Cancer

## Interventions

- **DRUG:** ESTRING
- **DRUG:** Replens
- **DRUG:** Vagifem

## Key facts

- **NCT ID:** NCT01984138
- **Lead sponsor:** Polly A. Niravath, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2013-09
- **Primary completion:** 2025-06-03
- **Final completion:** 2026-06
- **Target enrollment:** 33 (ACTUAL)
- **Last updated:** 2026-01-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01984138

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01984138, "REVIVE: Replens Versus Intra-Vaginal Estrogen for the Treatment of Vaginal Dryness on Aromatase Inhibitor Therapy". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01984138. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*